Effective April 1, 2024, Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc., was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company. Ms. Kestenberg, age 37, joined the Company as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Ms. Kestenberg served as the Company?s Senior Vice President, Compliance & Project Operations from April 2023 through March 2024, as Vice President, Compliance & Project Management and Acting Head of Analytical and Process Development from May 2021 through March 2023, as Vice President, Compliance & Project Management from April 2019 until May 2021 and as Senior Director, Compliance, Project Management & Clinical Operations from January 2018 through March 2019.

Prior to joining the Company, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics, Inc. and Merck & Co. Inc. Ms. Kestenberg holds a B.A. from the State University of New York at Albany and an M.S.J. from Seton Hall University. There have been no related party transactions between the Company and Ms. Kestenberg reportable under Item 404(a) of Regulation S-K, there are no arrangements or understandings between Ms. Kestenberg and any other person pursuant to which she was appointed as an officer reportable under Item 404(b) of Regulation S-K, and Ms. Kestenberg has no family relationships with any of our directors or executive officers.